Members-only Site   |   Print Page   |   Contact Us   |   Sign In   |   Register
Capitol Connections Article FDA to State Boards 1.24.14
Share |

FDA Communicates how State Boards of Pharmacy Should Report to the Agency

According to FDA - the following will provide enhanced communication with states.
The new law requires the Secretary to establish a mechanism to receive submissions from state boards of pharmacy concerning certain actions taken against compounding pharmacies or expressing concerns that a compounding pharmacy may be acting contrary to section 503A. This section is to be implemented in consultation with the National Association of Boards of Pharmacy (NABP). In addition, state boards of pharmacy must be notified when the Secretary receives certain state submissions or makes a determination that a compounding pharmacy is acting contrary to section 503A.

Until further information regarding how this process will work can be provided, States that wish to provide this information to FDA should submit the information by email to the following mailbox: StateCompounding@fda.hhs.gov. The agency intends to follow up with states that provide this information and to notify other states about the receipt of the information in accordance with the new law.

Association Management Software Powered by YourMembership.com®  ::  Legal